Harlan Waksal, Kadmon CEO (Richard Drew/AP Images)
FDA delays Kadmon’s priority review as apparent clampdown continues
Kadmon Holdings just lost their priority review.
The immunology biotech announced Wednesday that the FDA has pushed back the decision date for their graft-versus-host disease …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.